185 related articles for article (PubMed ID: 24530413)
1. Suramin inhibits hepatic tissue damage in hepatocellular carcinoma through deactivation of heparanase enzyme.
Tayel A; Abd El Galil KH; Ebrahim MA; Ibrahim AS; El-Gayar AM; Al-Gayyar MM
Eur J Pharmacol; 2014 Apr; 728():151-60. PubMed ID: 24530413
[TBL] [Abstract][Full Text] [Related]
2. Chemopreventive and hepatoprotective effects of Epigallocatechin-gallate against hepatocellular carcinoma: role of heparan sulfate proteoglycans pathway.
Darweish MM; Abbas A; Ebrahim MA; Al-Gayyar MM
J Pharm Pharmacol; 2014 Jul; 66(7):1032-45. PubMed ID: 24611903
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
4. Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers.
Elewa MA; Al-Gayyar MM; Schaalan MF; Abd El Galil KH; Ebrahim MA; El-Shishtawy MM
Clin Exp Metastasis; 2015 Jun; 32(5):479-93. PubMed ID: 25999065
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic effects of suramin against HepG2 cells through activation of intrinsic apoptotic pathway.
Tayel A; Ebrahim MA; Ibrahim AS; El-Gayar AM; Al-Gayyar MM
J BUON; 2014; 19(4):1048-54. PubMed ID: 25536615
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic activity of vitexicarpine in experimentally induced hepatocellular carcinoma: Impact on vascular endothelial growth factor pathway.
Hassoun SM; Abdel-Rahman N; Eladl EI; El-Shishtawy MM
Tumour Biol; 2017 Jun; 39(6):1010428317707376. PubMed ID: 28651490
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues.
Marchetti D; Reiland J; Erwin B; Roy M
Int J Cancer; 2003 Mar; 104(2):167-74. PubMed ID: 12569571
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic and partial hepatoprotective activity of sodium ascorbate against hepatocellular carcinoma through inhibition of sulfatase-2 in vivo and in vitro.
Alyoussef A; Al-Gayyar MMH
Biomed Pharmacother; 2018 Jul; 103():362-372. PubMed ID: 29669302
[TBL] [Abstract][Full Text] [Related]
9. The combination effects of Shen-Ling-Bai-Zhu on promoting apoptosis of transplanted H22 hepatocellular carcinoma in mice receiving chemotherapy.
Xi S; Peng Y; Minuk GY; Shi M; Fu B; Yang J; Li Q; Gong Y; Yue L; Li L; Guo J; Peng Y; Wang Y
J Ethnopharmacol; 2016 Aug; 190():1-12. PubMed ID: 27235019
[TBL] [Abstract][Full Text] [Related]
10. Downregulating the expression of heparanase inhibits the invasion, angiogenesis and metastasis of human hepatocellular carcinoma.
Zhang Y; Li L; Wang Y; Zhang J; Wei G; Sun Y; Shen F
Biochem Biophys Res Commun; 2007 Jun; 358(1):124-9. PubMed ID: 17467664
[TBL] [Abstract][Full Text] [Related]
11. Targeting p53/TRAIL/caspase-8 signaling by adiponectin reverses thioacetamide-induced hepatocellular carcinoma in rats.
Nazmy EA; El-Khouly OA; Zaki MMA; Elsherbiny NM; Said E; Al-Gayyar MMH; Salem HA
Environ Toxicol Pharmacol; 2019 Nov; 72():103240. PubMed ID: 31421311
[TBL] [Abstract][Full Text] [Related]
12. UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma.
Dong H; Yang X; Xie J; Xiang L; Li Y; Ou M; Chi T; Liu Z; Yu S; Gao Y; Chen J; Shao J; Jia L
Biochem Pharmacol; 2015 Jan; 93(2):151-62. PubMed ID: 25522955
[TBL] [Abstract][Full Text] [Related]
13. Chemopreventive and hepatoprotective roles of adiponectin (SULF2 inhibitor) in hepatocelluar carcinoma.
Al-Gayyar MM; Abbas A; Hamdan AM
Biol Chem; 2016 Mar; 397(3):257-67. PubMed ID: 26733159
[TBL] [Abstract][Full Text] [Related]
14. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma.
El-Assal ON; Yamanoi A; Ono T; Kohno H; Nagasue N
Clin Cancer Res; 2001 May; 7(5):1299-305. PubMed ID: 11350898
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of blocking β-catenin against hepatocellular carcinoma-induced activation of inflammation, fibrosis and tumor invasion.
Hassan HM; El-Kannishy SMH; Alattar A; Alshaman R; Hamdan AM; Al-Gayyar MMH
Biomed Pharmacother; 2021 Mar; 135():111216. PubMed ID: 33433352
[TBL] [Abstract][Full Text] [Related]
16. [Expression of heparanase mRNA and its clinical significance in primary hepatocellular carcinoma].
Zhang YL; Fu ZR; Ding GS; Fu H; Wang YH; Wang Q
Zhonghua Zhong Liu Za Zhi; 2003 Jul; 25(4):359-61. PubMed ID: 12921566
[TBL] [Abstract][Full Text] [Related]
17. Selective cytotoxic activity and protective effects of sodium ascorbate against hepatocellular carcinoma through its effect on oxidative stress and apoptosis
El-Far YM; Khodir AE; Noor AO; Almasri DM; Bagalagel AA; Diri RM; Kutbi HI; Al-Gayyar MMH
Redox Rep; 2020 Dec; 25(1):17-25. PubMed ID: 32172678
[No Abstract] [Full Text] [Related]
18. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis.
Vlodavsky I; Friedmann Y; Elkin M; Aingorn H; Atzmon R; Ishai-Michaeli R; Bitan M; Pappo O; Peretz T; Michal I; Spector L; Pecker I
Nat Med; 1999 Jul; 5(7):793-802. PubMed ID: 10395325
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of heparanase messenger RNA expression in hepatocellular carcinoma.
Ikeguchi M; Ueta T; Yamane Y; Hirooka Y; Kaibara N
J Surg Oncol; 2002 Nov; 81(3):148-54; disscusion 154. PubMed ID: 12407728
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the antitumor activity of platinum nanoparticles in the treatment of hepatocellular carcinoma induced in rats.
Medhat A; Mansour S; El-Sonbaty S; Kandil E; Mahmoud M
Tumour Biol; 2017 Jul; 39(7):1010428317717259. PubMed ID: 28720064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
